Cidara Therapeutics, Inc.
CDTX
$66.34
$2.213.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -98.33% | -94.52% | -86.96% | -78.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -98.33% | -94.52% | -86.96% | -78.78% |
| Cost of Revenue | 251.03% | 174.66% | 95.52% | -34.88% | -48.68% |
| Gross Profit | -513.41% | -504.30% | -423.77% | -46.46% | -951.30% |
| SG&A Expenses | 65.39% | 71.54% | 51.80% | 7.25% | -16.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 178.25% | 132.82% | 83.73% | -24.95% | -41.29% |
| Operating Income | -290.60% | -279.30% | -237.10% | -29.16% | -104.82% |
| Income Before Tax | -2.35% | -604.85% | -579.40% | -273.27% | -665.43% |
| Income Tax Expenses | -- | -- | -- | -97.50% | -108.01% |
| Earnings from Continuing Operations | -2.37% | -604.45% | -578.99% | -270.23% | -649.61% |
| Earnings from Discontinued Operations | -172.39% | 126.33% | -78.41% | 290.49% | -78.26% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.19% | -404.50% | -640.60% | -227.37% | -789.84% |
| EBIT | -290.60% | -279.30% | -237.10% | -29.16% | -104.82% |
| EBITDA | -291.69% | -280.31% | -237.93% | -29.14% | -105.60% |
| EPS Basic | 55.44% | -267.12% | -503.51% | -180.89% | -585.85% |
| Normalized Basic EPS | -74.09% | -96.90% | -100.98% | 7.35% | -83.37% |
| EPS Diluted | 55.46% | -266.89% | -502.81% | -180.85% | -584.48% |
| Normalized Diluted EPS | -74.09% | -96.90% | -100.98% | 7.35% | -46.77% |
| Average Basic Shares Outstanding | 153.47% | 93.55% | 45.07% | 21.79% | 16.69% |
| Average Diluted Shares Outstanding | 153.47% | 93.55% | 45.07% | 21.79% | 10.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |